Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.44 |
| ▸ | DRD3 | P35462 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD5 | P21918 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | PYGM | P11217 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784619 | 0.82 | LMNA (0.43) | DRD4DRD3LMNADRD2SMN1; SMN2 | |
| SCHEMBL6789606 | 0.78 | CYBB (0.49) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL6791293 | 0.78 | MAPT (0.53) | DRD3LMNADRD2ALDH1A1MAPT | |
| SCHEMBL3785990 | 0.77 | MAPT (0.47) | DRD4DRD3LMNADRD2DRD5 | |
| SCHEMBL6788466 | 0.76 | HRH4 (0.44) | LMNASMN1; SMN2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL3236690 | 0.75 | ROCK2 (0.53) | LMNASMN1; SMN2ALDH1A1POLBCYP1A2 | |
| SCHEMBL6789794 | 0.75 | SCN9A (0.44) | LMNASMN1; SMN2ALDH1A1POLBMAPT | |
| SCHEMBL6788991 | 0.75 | TDP1 (0.44) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL6788753 | 0.72 | KMT2A (0.50) | LMNAKDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL6785059 | 0.72 | HRH4 (0.43) | LMNASMN1; SMN2ALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | DRD4 412/4885DRD3 158/4885LMNA 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.